One-Third in the U.S. May Be Diabetic by 2050
One out of every three U.S. adults may suffer from type 2 diabetes by 2050, according to a new Centers for Disease Control and Prevention (CDC) report published in the journal Population Health Metrics. Currently, 10% of U.S. adults suffer from diabetes, and 25% percent of those with diabetes are still undiagnosed.
One out of every three U.S. adults may suffer from type 2 diabetes by 2050, according to a new Centers for Disease Control and Prevention (CDC) report published in the journal Population Health Metrics. Currently, 10% of U.S. adults suffer from diabetes, and 25% percent of those with diabetes are still undiagnosed.
Rising obesity rates will be a significant contributor. The CDC states that groups such as African Americans and Hispanics are now also more at risk for developing diabetes. In addition, the general population at large is now living longer with the disease.
Diabetes was the seventh leading cause of death in 2007 and is the number-one cause for adult blindness, kidney failure, and non-accident-related limb amputation, according to the report. Moreover, it increases the risk of heart attacks and stroke, and has also been linked to dementia and some forms of cancer and lung disease.
CDC estimates that diabetes currently costs the U.S. $116 billion in medical costs, annually.
“These are alarming numbers that show how critical it is to change the course of type 2 diabetes,” said Ann Albright, PhD, RD, director of CDC’s Division of Diabetes Translation. “Successful programs to improve lifestyle choices on healthy eating and physical activity must be made more widely available, because the stakes are too high and the personal toll too devastating to fail.”
Read the CDC report here.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
